Peptide profile · Weight Management
Pemvidutide
Balanced dual GLP-1/glucagon receptor agonist with no dose titration required and breakthrough therapy designation for MASH.
Molecular formula
C182H275N39O54
- CAS number
- 2538014-94-5
- PubChem
- Not available (investigational compound)
- Developed · 2022
- Viking Therapeutics research team, Viking Therapeutics, Inc.
Amino acid sequence
29-amino acid dual agonist peptide with EuPort glycolipid conjugation for extended half-life1.2 – 2.4mg
Every documented dose level
| Phase | Dose | Frequency |
|---|---|---|
| 48 weeks | 1.2 mg | Once weekly |
| 48 weeks | 1.8 mg | Once weekly |
| 48 weeks | 2.4 mg | Once weekly |
Best for adults seeking substantial weight loss without complex dose titration & individuals with concurrent mash/nafld and obesity requiring dual-target therapy
Best for
Adults seeking substantial weight loss without complex dose titration
Pemvidutide is particularly well-suited for individuals focused on adults seeking substantial weight loss without complex dose titration. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Individuals with concurrent MASH/NAFLD and obesity requiring dual-target therapy
Pemvidutide is particularly well-suited for individuals focused on individuals with concurrent mash/nafld and obesity requiring dual-target therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .
Patients with metabolic syndrome who need comprehensive risk factor improvement
Pemvidutide is particularly well-suited for individuals focused on patients with metabolic syndrome who need comprehensive risk factor improvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those interested in investigational dual agonist therapies with strong early data
Pemvidutide is particularly well-suited for individuals focused on those interested in investigational dual agonist therapies with strong early data. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach .
Consider alternatives if
Do not use if
- Personal or family history of medullary thyroid carcinoma or MEN2 syndrome
- Known hypersensitivity to pemvidutide or formulation components
- History of acute pancreatitis
- Severe hepatic decompensation (Child-Pugh C cirrhosis)
Use with caution if
- You are taking other medications—discuss potential interactions with your healthcare provider
- You have a history of liver or kidney disease
- You are elderly or have multiple medical conditions
- You are planning surgery in the near future—inform your surgeon about Pemvidutide use
- You have any chronic health conditions that require regular monitoring
Not sure?
Compare Pemvidutide with similar peptides to find the best fit for your goals.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- Front of thighs—middle to upper portion of the outer leg
- Back of upper arm—outer area (may need assistance from another person)
The Pemvidutide injection guide covers reconstitution · step-by-step technique · storage · a sample daily schedule.
3 common side effects · 2 serious
Pemvidutide (ALT-801, developed by Altimmune; a GLP-1/glucagon dual agonist) completed Phase IIb obesity trials with favorable cardiovascular safety profile.
Gastrointestinal side effects (nausea, vomiting, diarrhea) occur in 30-40% of subjects, more prominent than GLP-1 monotherapy due to GCG receptor activation. Pancreatitis risk and elevated calcitonin levels require monitoring.
No serious cardiac safety signals despite dual receptor activation; heart rate increases of 5-10 bpm observed.
Phase IIb RCTs (n=500+) demonstrate dual GLP-1R/GCR mechanism through glucose-dependent hyperglycemia correction and weight loss up to 18% over 52 weeks. Fasting lipid improvements with 20-30% triglyceride reductions and 10-15% LDL decreases measured via standard lipid panels.
Mechanistic studies via indirect calorimetry show increased energy expenditure; pancreatic imaging via MRI shows no structural changes.
Common side effects · experienced by some users
Nausea
Most commonly reported adverse event, generally mild and often resolving within the first few weeks of treatment.
Management
Eat smaller, more frequent meals. Avoid high-fat or greasy foods. Stay well hydrated.
Diarrhea
Mild to moderate gastrointestinal disturbance occurring in a meaningful proportion of trial participants.
Management
Maintain hydration, consider bland diet temporarily, and consult prescriber if persistent beyond 2 weeks.
Headache
Reported in clinical trials, typically mild and self-resolving without intervention.
Management
Standard analgesics as needed. Ensure adequate hydration and regular meals.
Serious side effects
Acute Pancreatitis
Rare but serious risk consistent with the GLP-1 receptor agonist class. Requires immediate clinical evaluation.
Management
Discontinue pemvidutide immediately. Seek emergency medical attention. Do not rechallenge after confirmed pancreatitis.
Severe Gastrointestinal Disturbance
Combined GLP-1R and GcgR activation can produce potent GI effects including severe nausea, vomiting, diarrhea, and abdominal pain, potentially leading to dehydration or electrolyte imbalances.
Management
Use gradual dose titration schedule; administer with food to reduce nausea; ensure adequate hydration and electrolyte replacement; consider antiemetics; monitor for signs of dehydration; educate on expected GI effects during titration.
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Pemvidutide
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Pemvidutide should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- SafeMetformin — May be used together under medical guidance.
- SafeStructured Exercise Program — May be used together under medical guidance.
- SafeVitamin E (for MASH patients) — May be used together under medical guidance.
With medications
- CautionOther GLP-1 Receptor Agonists — Use with caution—discuss with your healthcare provider.
- CautionSulfonylureas — Use with caution—discuss with your healthcare provider.
- CautionInsulin (without dose adjustment) — Use with caution—discuss with your healthcare provider.
With supplements
- SafeMultivitamins — Generally safe to take alongside Pemvidutide. Space doses apart if taking oral formulations to ensure optimal absorption.
- SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Moderate human trials · first signs weeks 1-4
Evidence level
Moderate human trials
(Phase 1-2)
80/100
Regulatory status
Research compound
Onset of effects
Moderate
(1-2 weeks)
How it works
Pemvidutide is a next-generation dual peptide agonist that activates both GLP-1 receptors AND glucagon receptors for metabolic benefits.
This dual activation produces weight loss through appetite suppression plus increased fat burning through metabolic acceleration, creating a powerful synergistic effect for obesity treatment.
The deeper mechanism
Pemvidutide is a synthetic peptide agonist that simultaneously activates GLP-1 receptor (GLP-1R) and glucagon receptor (GcgR), both Gs-coupled GPCRs that increase cAMP and activate PKA signaling.
GLP-1R activation in hypothalamic POMC neurons and hindbrain NTS neurons produces anorexigenic signaling and enhanced satiety, while GcgR activation in hepatocytes increases gluconeogenesis and lipolysis, promoting hepatic fat oxidation and increased metabolic rate.
The dual GLP-1R/GcgR agonism produces synergistic weight loss exceeding single-target GLP-1R agonists: GLP-1R component provides appetite suppression (~15-20% weight loss potential), while GcgR component promotes metabolic acceleration and fat mobilization (~8-15% additional weight loss).
Glucose-dependent insulin secretion is enhanced through GLP-1R activation while hepatic glucose production is modulated through both pathways.
What to expect
Weeks 1-4
What you might notice
- Full therapeutic dose from day one (no titration)
- Early appetite reduction and gastrointestinal adjustment
- Initial weight loss of 3-5% typically observed
- Liver fat reduction begins
What's normal
- Full integration of Pemvidutide into physiological systems is established
- Long-term Pemvidutide response remains personalized to your physiology
- Pemvidutide tolerance is well-maintained with consistent dosing
What's next
- Maintain your established Pemvidutide protocol for sustained benefits
- Continue periodic monitoring to confirm Pemvidutide efficacy
- Review comprehensive Pemvidutide response with your provider
Weeks 4-24
What you might notice
- Progressive weight loss reaches 8-12%
- Significant liver fat reduction (up to 75% relative decrease by MRI)
- Improvements in transaminases and metabolic parameters become apparent
- MASH resolution observed in clinical studies
What's normal
- Pemvidutide is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Pemvidutide's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Pemvidutide dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Weeks 24-48+
What you might notice
- Weight loss continues toward plateau of 13-16%
- Sustained improvements in hepatic histology, lipid profiles, and cardiovascular risk markers
- Ongoing metabolic benefits with continued treatment
What's normal
- Characteristic effects of Pemvidutide are becoming established
- Repeated Pemvidutide doses show predictable pharmacological effects
- Pemvidutide tolerance patterns are developing normally
What's next
- Evaluate Pemvidutide efficacy relative to treatment goals
- Discuss potential protocol adjustments with your healthcare provider
- Continue regular Pemvidutide monitoring at current frequency
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Pemvidutide over time
- Reduction in symptom frequency or severity
Signs it's working
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results?
Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
15 registered studies, none currently enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 1,315 people took part in the studies that actually administered Pemvidutide. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
Altimmune, Inc.
RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Altimmune, Inc.
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
Altimmune, Inc.
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Pemvidutide is named as an intervention; studies that only mention it in passing are not.
Why doesn't pemvidutide require dose titration?
Pemvidutide's balanced 1:1 GLP-1/glucagon agonism and specific pharmacological profile produce tolerability at therapeutic doses from initiation. Unlike other incretin therapies where high-dose GLP-1 activity causes severe initial nausea requiring gradual uptitration, pemvidutide's balanced receptor engagement allows therapeutic dosing from the first injection. This simplifies treatment and may improve early adherence.
What is the IMPACT trial and what did it show?
IMPACT was a Phase 2 randomized controlled trial evaluating pemvidutide in patients with biopsy-confirmed MASH. At 24 weeks, the 1.2 mg dose achieved a 58% MASH histological resolution rate, and patients experienced up to 75% relative reduction in liver fat content as measured by MRI-PDFF. These results supported FDA Breakthrough Therapy and Fast Track designations.
How does pemvidutide compare to other dual agonists like survodutide or mazdutide?
Pemvidutide is differentiated by three features: balanced 1:1 GLP-1/glucagon receptor agonism (versus the GLP-1-predominant profiles of some competitors), no dose titration requirement (simplifying treatment initiation), and the EuPort glycolipid conjugation technology (versus traditional fatty acid acylation). It is currently in Phase 2b/3, while survodutide and mazdutide are at more advanced stages. Head-to-head comparisons have not been conducted.
Is pemvidutide FDA approved?
No. As of early 2026, pemvidutide is an investigational compound in Phase 2b/3 clinical development. It has received FDA Breakthrough Therapy designation and Fast Track designation for MASH, which may accelerate the regulatory review process. Phase 3 trials (VENTURE program) are underway for both obesity and MASH indications.
What is the EuPort glycolipid technology?
EuPort is Altimmune's proprietary glycolipid conjugation platform that covalently attaches a glycolipid moiety to the peptide. This modification enables strong non-covalent binding to serum albumin in circulation, which shields the peptide from enzymatic degradation and renal clearance. The result is a half-life of approximately 110 hours (4.6 days), supporting once-weekly subcutaneous administration.
What weight loss was achieved in clinical trials?
In the Phase 2b MOMENTUM trial, pemvidutide 2.4 mg achieved approximately 15.6% placebo-adjusted mean body weight loss at 48 weeks in adults with obesity or overweight. The 1.8 mg dose achieved approximately 13.0% weight loss. These results were achieved without dose titration, meaning the full therapeutic effect began from the first injection.
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Pemvidutide, on one page.
Pemvidutide dosing protocol